Confident Investing Starts Here:
- Quickly and easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
- Receive undervalued, market resilient stocks straight to you inbox with TipRanks' Smart Value Newsletter
An update from Abbisko Cayman Limited ( (HK:2256) ) is now available.
Abbisko Cayman Limited has announced its upcoming Annual General Meeting (AGM) scheduled for June 18, 2025, in Shanghai. Key agenda items include the approval of the company’s audited financial statements for 2024, re-election of directors, and authorization for the board to fix directors’ remuneration. Additionally, the company seeks approval to re-appoint Ernst & Young as auditors and to authorize the board to manage share allotments, potentially impacting the company’s capital structure and shareholder value.
The most recent analyst rating on (HK:2256) stock is a Buy with a HK$18.00 price target. To see the full list of analyst forecasts on Abbisko Cayman Limited stock, see the HK:2256 Stock Forecast page.
More about Abbisko Cayman Limited
Abbisko Cayman Limited is a company incorporated in the Cayman Islands, operating primarily in the biotechnology sector. It focuses on the development of innovative therapies and pharmaceuticals, aiming to address unmet medical needs.
Average Trading Volume: 6,511,083
Technical Sentiment Signal: Buy
Current Market Cap: HK$5.4B
For an in-depth examination of 2256 stock, go to TipRanks’ Stock Analysis page.